The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Lung Cancer MORE >>

According to new findings, tumor mutational burden showed promise as a predictive biomarker for survival benefit in patients with advanced non–small cell lung cancer (NSCLC) treated with the PD-L1 inhibitor durvalumab (Imfinzi) as initial therapy versus chemotherapy, even though there was no difference seen between the 2 treatment groups in the primary analysis of the randomized trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.